Pung et al., 2023 - Google Patents
Generation of peptides using phage display technology for cancer diagnosis and molecular imagingPung et al., 2023
View HTML- Document ID
- 14931445192484231937
- Author
- Pung H
- Tye G
- Leow C
- Ng W
- Lai N
- Publication year
- Publication venue
- Molecular Biology Reports
External Links
Snippet
Cancer is one of the leading causes of mortality worldwide; nearly 10 million people died from it in 2020. The high mortality rate results from the lack of effective screening approaches where early detection cannot be achieved, reducing the chance of early …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Targeting peptide‐based probes for molecular imaging and diagnosis | |
| Pung et al. | Generation of peptides using phage display technology for cancer diagnosis and molecular imaging | |
| Hong et al. | Molecular imaging with nucleic acid aptamers | |
| US10124077B2 (en) | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma | |
| Zhu et al. | Novel glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescent imaging | |
| US20220175977A1 (en) | Compounds and methods for the detection of trpv-6 cancers and drug delivery | |
| Shipunova et al. | Comparative evaluation of engineered polypeptide scaffolds in HER2-targeting magnetic nanocarrier delivery | |
| Li et al. | Application of phage-displayed peptides in tumor imaging diagnosis and targeting therapy | |
| Zhou et al. | A novel near-infrared fluorescent probe TMTP1-PEG4-ICG for in vivo tumor imaging | |
| Zhang et al. | Construction of targeting-peptide-based imaging reagents and their application in bioimaging | |
| Cao et al. | Development of a novel HER2-targeted peptide probe for dual-modal imaging of tumors | |
| Fan et al. | Investigation into the biological impact of block size on cathepsin S-degradable HPMA copolymers | |
| Paganin-Gioanni et al. | Fluorescence imaging agents in cancerology | |
| Liu et al. | iRGD-Targeted Biosynthetic Nanobubbles for Ultrasound Molecular Imaging of Osteosarcoma | |
| Soendergaard et al. | In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging | |
| Kang et al. | Targeted imaging of esophageal adenocarcinoma with a near-infrared fluorescent peptide | |
| CN117777237A (en) | A polypeptide targeting BCMA and its application | |
| Chopra | ZW800-1, a zwitterionic near-infrared fluorophore, and its cyclic RGD peptide derivative cyclo-(RGDyK)-ZW800-1 | |
| CN113717249A (en) | CD47 targeted polypeptide, molecular probe and application thereof | |
| Cimen et al. | Phage Display–Selected Peptides: Research and Clinical Applications in Cancer Imaging | |
| Cochran et al. | Phage display and molecular imaging: expanding fields of vision in living subjects | |
| Liu et al. | PEGylated and non-PEGylated TCP-1 probes for imaging of colorectal cancer | |
| CN112876538B (en) | Polypeptide targeting neovascular marker CD105 and its application | |
| Tian et al. | Near-infrared-dye labeled tumor vascular-targeted dimer GEBP11 peptide for image-guided surgery in gastric cancer | |
| Yuan et al. | Identification of a Novel Vascular Endothelial Growth Factor Receptor-3-Targeting Peptide for Molecular Imaging of Metastatic Lymph Nodes |